Ticker

Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S  BH-30643 was recently granted Fast Track designation by the FDA for the treatment of C797S-positive resistance in EGFR-mutant NSCLC, a setting where no oral targeted therapies are approved SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- BlossomHill…

SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BH-30643 for the treatment of adult patients…

BlossomHill Therapeutics, Inc. (NASDAQ: BLSM - Get Free Report) Director Bihua Chen acquired 312,500 shares of the business's stock in a transaction dated Monday, August 10th. The shares were bought at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the acquisition, the director owned 3,614,034 shares of the company's stock,

SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , (“BlossomHill Therapeutics”), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop innovative small molecule medicines for the treatment of cancer, today announced the pricing of its upsized initial public offering of 9,375,000 shares of common stock at a price to the public of $16.00 per…

BlossomHill Therapeutics is seeking a $125 million IPO to advance its oncology pipeline, focused on EGFR-mutant NSCLC. I see early clinical data for BH-30643 as promising, supporting a potential accelerated FDA pathway for this large, fast-growing market. IPO proceeds will fund Phase 2 trials, pipeline expansion, and provide runway into Q1 2028, supporting long-term value creation.